TMO — Thermo Fisher Scientific Balance Sheet
0.000.00%
Last trade - 00:00
- $222.34bn
- $249.28bn
- $42.86bn
- 83
- 17
- 71
- 59
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2,436 | 10,353 | 4,477 | 8,526 | 8,080 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4,952 | 6,472 | 8,945 | 9,427 | 9,664 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 11,893 | 21,957 | 20,113 | 25,229 | 24,589 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5,448 | 6,687 | 9,864 | 10,873 | 11,004 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 58,381 | 69,052 | 95,123 | 97,154 | 98,726 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 6,197 | 10,304 | 13,436 | 17,010 | 14,012 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 28,706 | 34,545 | 54,330 | 53,176 | 51,991 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 29,675 | 34,507 | 40,793 | 43,978 | 46,735 |
Total Liabilities & Shareholders' Equity | 58,381 | 69,052 | 95,123 | 97,154 | 98,726 |
Total Common Shares Outstanding |